Maven Securities LTD Invests $5.88 Million in Organon & Co. $OGN

Maven Securities LTD bought a new position in shares of Organon & Co. (NYSE:OGN) in the second quarter, HoldingsChannel.com reports. The institutional investor bought 434,200 shares of the company’s stock, valued at approximately $5,879,000.

Other hedge funds have also recently bought and sold shares of the company. Royal Bank of Canada increased its position in shares of Organon & Co. by 53.4% in the first quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock worth $5,374,000 after acquiring an additional 125,648 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Organon & Co. by 126.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock worth $21,370,000 after purchasing an additional 801,307 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Organon & Co. by 2.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company’s stock worth $15,530,000 after purchasing an additional 26,640 shares during the period. Focus Partners Wealth boosted its position in Organon & Co. by 33.2% during the 1st quarter. Focus Partners Wealth now owns 55,875 shares of the company’s stock worth $832,000 after purchasing an additional 13,925 shares during the period. Finally, XTX Topco Ltd acquired a new stake in Organon & Co. in the 2nd quarter valued at $107,000. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Five research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Organon & Co. currently has a consensus rating of “Reduce” and a consensus target price of $11.40.

Organon & Co. Stock Down 0.1%

NYSE OGN opened at $13.77 on Wednesday. The company has a quick ratio of 1.44, a current ratio of 1.95 and a debt-to-equity ratio of 8.43. Organon & Co. has a fifty-two week low of $5.69 and a fifty-two week high of $13.78. The business has a 50 day moving average price of $13.62 and a two-hundred day moving average price of $11.43. The stock has a market cap of $3.61 billion, a PE ratio of 17.88, a P/E/G ratio of 1.28 and a beta of 1.52.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Organon & Co.’s payout ratio is presently 10.39%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.